A sulfur-enriched form of lipoic acid proposed to protect the chemically spoiled signal that wakes resting muscle stem cells. Evidence is cell-culture and one short mouse experiment; no humans studied. Lipoic acid itself carries a small but real link to an autoimmune reaction causing dangerously low blood sugar. Obtaining it remains research-grade; mechanical loading, its enabling condition, works without it. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting glucose | 70–86 mg/dL (3.9–4.8 mmol/L) | Detects the glucose-lowering effect carried by the released parent compound |
| HbA1c | 4.8–5.4% | Tracks glucose control over months rather than at one moment |
| Fasting insulin | 2–5 μIU/mL | Very high insulin with low glucose points to insulin autoantibodies rather than a pancreatic tumour |
| C-peptide | 1.0–2.0 ng/mL | Separates an autoantibody-driven reaction from injected insulin as the cause of low glucose |
| Insulin autoantibodies (IAA) | Negative | The defining test for the autoimmune insulin reaction linked to the parent compound |
| Creatine kinase (CK) | 60–200 U/L | Flags muscle injury that would otherwise confound any muscle endpoint |
| Alanine aminotransferase (ALT) | 10–26 U/L (men), 10–19 U/L (women) | The released parent compound undergoes heavy first-pass liver handling |
| Appendicular lean mass index (ALMI) | Above 7.0 kg/m² (men), above 5.5 kg/m² (women) | The outcome the intervention is meant to preserve |
| Plasma total sulfane sulfur | No established target range; track the change from the individual's own baseline instead | The only direct read-out of trisulfide exposure |
Cadence: Baseline set before any exposure; glucose and symptom review at 2 weeks and 4 weeks; the full glucose and enzyme panel at 12 weeks, then every 6 months; body composition and strength repeated at 6 and 12 months.